Key Highlights

  • Cash, cash equivalents and short-term investments totaled USD 254.7 million at September 30, 2026, including USD 10.8 million in cash and USD 243.9 million in Money Market and U.S. Treasury holdings.
  • A recoverability test of long-lived assets, triggered by a sustained market Capitalization decline and lower LDD sales volumes, found the carrying amount recoverable, so no Impairment was recorded.
  • A securities class action filed July 22, 2025 survived a motion to dismiss on May 21, 2026, and discovery is ongoing.
  • A hypothetical 1.00% change in interest rates would not materially affect the Fair Value of the marketable securities or interest income.

Impairment Review Follows Falling Market Value and LDD Volumes

RxSight (NASDAQ:RXST) filed its Quarterly Report for the period ended September 30, 2026 on November 3, 2026. The filing says that during the quarter the company identified indicators of possible impairment of its long-lived assets, specifically a sustained decline in its market capitalization and lower sales volumes of its LDD product line, which the filing refers to by that abbreviation. It tested the assets, which it treats as a single asset group, by comparing estimated undiscounted future cash flows with their carrying value. The cash flows exceeded the carrying amount, so no impairment loss was recorded.

How Impairment Tests Work and Why the Judgment Matters

An impairment review asks whether future operating cash flows from an asset group will cover its book value. If they fall short, the asset is written down to fair value, usually estimated through discounted cash flows. The company warns that these estimates depend on forecasts of growth rates, margins, discount rates and regulatory conditions, and that its long-lived Assets could become impaired in future if expectations are not met. A write-down would be non-cash, but it would reduce reported Earnings and assets. Liquidity looks sound: USD 254.7 million of cash and short-term investments sits mostly in money market funds and Treasury securities maturing within twelve months, held for liquidity and capital preservation, and foreign currency exposure is described as de minimis. Revenue and earnings figures were not part of the extract used for this article.

Securities Lawsuit, Supply Risks and What to Watch

The legal section is the larger risk disclosure. A putative securities class action filed July 22, 2025 in federal court in the Central District of California alleges the company and certain officers made misleading statements about Demand and financial guidance. Related cases were consolidated on October 6, 2025, a motion to dismiss was filed February 13, 2026 and denied on May 21, 2026, and the company answered on June 9, 2026. Plaintiffs seek unspecified damages, and a Shareholder derivative action was filed August 18, 2025 against certain officers and directors. The company also depends on single and sole source suppliers without long-term agreements, uses purchase orders covering 18 to 24 months, and cites tariffs and Inflation as uncertainties. Allegations are not findings, and outcomes are uncertain. Next checkpoints include any further LDD sales commentary and litigation rulings.

Where Things Stand

RxSight (NASDAQ:RXST) ran the test because accounting rules require a review when the stock's market value falls for a sustained period and product volumes weaken, not because the company recorded a loss on its assets. It passed, and management says its disclosure controls were effective. The balance of evidence is cautious: liquidity of USD 254.7 million is a strength, while lower LDD volumes, the ongoing class action and supply concentration are real risks. The supplied extract does not show quarterly revenue or profit, so the scale of the slowdown is unknown. Watch the next earnings report, litigation developments and any change in the impairment assessment.